Our boxes are unpacked and our desks are organized! We’ve officially moved into our new spot in Boston. With new lab and office spaces, we’re more ready than ever to get to work and help protect the world from cardiovascular disease.

After a month-long cornhole competition, we’re excited to finally congratulate our winners Andrew Ashe and Andrew Bellinger. While these two champs took the gold, we’re proud of all the participants for bringing their A game.

We’re looking for an experienced and enthusiastic Clinical Operations Manager to provide operational management and oversight of clinical trials as we develop our base-editing medicines for cardiovascular disease. Read more here: vervetx.com/open-positions… #biotechjobs #bostonjobs

Following our preclinical data presentation for our newly nominated ANGPTL3 development candidate, VERVE-201, hear from our Exec. Director, Genomic Medicine Amit V. Khera as he explains the significance behind the data & what it could mean for patients with cardiovascular disease.

Our co-founder and CEO Sek Kathiresan MD spoke at Chardan’s Annual Genetic Medicines Conference. He provided an overview of Verve & how single-course treatment for ASCVD could address a key unmet need — getting LDL-C as low as possible for as long as possible. #ChardanGMConf #CGMC2022

We had a great discussion during our fireside chat at the Jefferies Cell and Genetic Medicine Summit yesterday which entailed how we plan to develop our two lead product candidates, VERVE-101 and VERVE-201, to treat patients with CVD. See the replay here: wsw.com/webcast/jeff25…

On #WorldHeartDay , we're showing support for CVD patients. As part of our vision, we are taking a stepwise approach to clinical development with our single-course gene editing programs. Learn more about our plans to protect the world from CVD here: vervetx.com

Our co-founder and CEO Sek Kathiresan MD, M.D. spoke at the Guggenheim Partners Nantucket Therapeutics Conference this morning. Tune in to the replay here:
ir.vervetx.com/events/event-d…

Tomorrow is Familial Hypercholesterolemia (FH) Awareness Day. We're initially focusing on disease populations that have genetically driven, life-long & severely elevated LDL-C, such as FH. Learn more about how we're addressing FH here: vervetx.com/pipeline/

#KnowFH

Along with bringing our loved ones to American Heart Association’s Heart Walk earlier this month, we were pleased to sponsor the Honor Wall. The Honor Wall gives participants an opportunity to honor loved ones impacted by heart disease or stroke, while taking action to lower their own risk.

We're pleased to announce the clearance of Clinical Trial Authorisation application by the U.K. Medicines and Healthcare products Regulatory Agency for VERVE-101 as a potential treatment for patients with heterozygous familial hypercholesterolemia. ir.vervetx.com/news-releases/…

This weekend, we participated in the American Heart Association's 2022 Boston Heart Walk! We brought our family & friends along to join us & helped raise lifesaving funds to fight heart disease and stroke. Learn more about the Heart Walk & how you can donate here: www2.heart.org/site/TR/HeartW…

In advance of the American Heart Association’s 2022 Boston Heart Walk this weekend, we asked our team why they walk. We’re looking forward to getting our hearts pumping, honoring survivors, and raising lifesaving funds for cardiovascular disease research.

After a week of relaxing and recharging, we’re ready to be back in action! But first, check out some of our team’s favorite views and occasions from our 2022 summer shutdown.

A new Verve space is under way at Fenway in Boston! We’re excited about our continued growth, including more lab and office spaces, as we lean further into our mission of developing base editing medicines to treat patients with #cardiovasculardisease .

Our CEO Sek Kathiresan MD shared our approach to treating cardiovascular disease with Mitch and Daniel from the External Medicine Podcast. Check out the full episode here: externalmedicinepodcast.com/sekar-kathires…

There’s nothing wrong with a little bit of healthy competition! Over the last few weeks, our team has enjoyed the summer sun and engaged in a cornhole tournament. May the best of the best take the gold.🥇

Yesterday, we presented preclinical data for our newly nominated ANGPTL3 development candidate, VERVE-201, which is initially being developed as a treatment of homozygous familial hypercholesterolemia (HoFH). ir.vervetx.com/static-files/3… #ESCCongress #ESC2022
#cardiovasculardisease

Hitting the half year mark calls for a break! We’re using next week to reflect on our growth, rest, and recharge so that we can come back stronger than ever to pioneer a new approach to the care of #cardiovascular disease. #InsideVerve